BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions

Practical Radiation Oncology

Volumn 4, Issue 5, 2014, Pages e213-e216

  Wallach, Jonathan B ^a   Rietschel, Petra ^b   Kalnicki, Shalom ^a   Fox, Jana L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Medical Oncology Bayer Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; BACTERIUM DETECTION; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DECUBITUS; DESQUAMATION; EGGERTHELLA LENTA; ERYTHEMA; FEMALE; HEARING IMPAIRMENT; HUMAN; LIMB WEAKNESS; MELANOMA; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVOTELLA LOESCHEII; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EQUIPMENT; RASH; SEPSIS; SHOULDER DISEASE; VERY ELDERLY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMPLICATION; FATALITY; LYMPH NODE METASTASIS; MOUTH DISEASES; PATHOLOGY; SECONDARY; SKIN DISEASES; TUMOR INVASION;

AGED, 80 AND OVER; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FATAL OUTCOME; FEMALE; HUMANS; INDOLES; LYMPHATIC METASTASIS; MELANOMA; MOUTH DISEASES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN DISEASES; SULFONAMIDES;

EID: 84925342607     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2013.10.007     Document Type: Article

References (13)

1. Cancer Facts & Figures 2012 2012, American Cancer Society, American Cancer Society, Atlanta, GA.
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
3. Garbe C., Eigentler T.K., Keilholz U., et al. Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 2011, 16:5-24.
4. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
5. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
6. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
7. Smalley K.S., Sondak V.K. Melanoma-an unlikely poster child for personalized cancer therapy. N Engl J Med 2010, 363:876-878.
8. Wellbrock C., Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010, 80:561-567.
9. Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246.
10. Sambade M.J., Peters E.C., Thomas N.E., Kaufmann W.K., Kimple R.J., Shields J.M. Melanoma cells show a heterogenous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011 Mar, 98:394-399.
11. Dummer R., Rinderknecht J., Goldinger S.M. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012, 366:480-481.
12. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
13. Boussemart L., Boivin C., Claveau J., et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013, 149:855-857.